PancreasPub Date : 2024-08-01DOI: 10.1097/MPA.0000000000002334
Hester C Timmerhuis, Rejoice F Ngongoni, Amy Li, Sean P McGuire, Kyle A Lewellen, Monica M Dua, Komal Chughtai, Nicholas J Zyromski, Brendan C Visser
{"title":"The Potential Clinical Benefits of Direct Surgical Transgastric Pancreatic Necrosectomy for Patients With Infected Necrotizing Pancreatitis.","authors":"Hester C Timmerhuis, Rejoice F Ngongoni, Amy Li, Sean P McGuire, Kyle A Lewellen, Monica M Dua, Komal Chughtai, Nicholas J Zyromski, Brendan C Visser","doi":"10.1097/MPA.0000000000002334","DOIUrl":"10.1097/MPA.0000000000002334","url":null,"abstract":"<p><strong>Objective: </strong>Surgical transgastric pancreatic necrosectomy (STGN) has the potential to overcome the shortcomings (ie, repeat interventions, prolonged hospitalization) of the step-up approach for infected necrotizing pancreatitis. We aimed to determine the outcomes of STGN for infected necrotizing pancreatitis.</p><p><strong>Materials and methods: </strong>This observational cohort study included adult patients who underwent STGN for infected necrosis at two centers from 2008 to 2022. Patients with a procedure for pancreatic necrosis before STGN were excluded. Primary outcomes included mortality, length of hospital and intensive care unit (ICU) stay, new-onset organ failure, repeat interventions, pancreatic fistulas, readmissions, and time to episode closure.</p><p><strong>Results: </strong>Forty-three patients underwent STGN at a median of 48 days (interquartile range [IQR] 32-70) after disease onset. Mortality rate was 7% (n = 3). After STGN, the median length of hospital was 8 days (IQR 6-17), 23 patients (53.5%) required ICU admission (2 days [IQR 1-7]), and new-onset organ failure occurred in 8 patients (18.6%). Three patients (7%) required a reintervention, 1 (2.3%) developed a pancreatic fistula, and 11 (25.6%) were readmitted. The median time to episode closure was 11 days (IQR 6-22).</p><p><strong>Conclusions: </strong>STGN allows for treatment of retrogastric infected necrosis in one procedure and with rapid episode resolution. With these advantages and few pancreatic fistulas, direct STGN challenges the step-up approach.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":"53 7","pages":"e573-e578"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141580500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PancreasPub Date : 2024-08-01Epub Date: 2024-05-13DOI: 10.1097/MPA.0000000000002341
Juliana C Levy, Abby Wong, Huaibin M Ko, John Chabot
{"title":"Primary Angiomyolipoma of the Distal Pancreas.","authors":"Juliana C Levy, Abby Wong, Huaibin M Ko, John Chabot","doi":"10.1097/MPA.0000000000002341","DOIUrl":"10.1097/MPA.0000000000002341","url":null,"abstract":"","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e629-e630"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140915805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PancreasPub Date : 2024-07-01DOI: 10.1097/MPA.0000000000002332
Takato Inoue, Koichiro Mandai, Koji Uno
{"title":"Multiple Carcinomas In Situ Scattered Throughout the Pancreas Diagnosed by Assessing Focal Pancreatic Parenchymal Atrophy.","authors":"Takato Inoue, Koichiro Mandai, Koji Uno","doi":"10.1097/MPA.0000000000002332","DOIUrl":"10.1097/MPA.0000000000002332","url":null,"abstract":"","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":"53 6","pages":"e544-e545"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PancreasPub Date : 2024-07-01Epub Date: 2024-03-12DOI: 10.1097/MPA.0000000000002324
Remya Radhakrishnan, Shalini G Hegde
{"title":"Acute Pancreatitis: A Red Herring in Burkitt's Lymphoma.","authors":"Remya Radhakrishnan, Shalini G Hegde","doi":"10.1097/MPA.0000000000002324","DOIUrl":"10.1097/MPA.0000000000002324","url":null,"abstract":"","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e543-e544"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database: The SUISEI Study.","authors":"Hideki Ueno, Kyoko Shimizu, Ayako Fukui, Masahiro Nii, Ryo Koto, Michiaki Unno","doi":"10.1097/MPA.0000000000002321","DOIUrl":"10.1097/MPA.0000000000002321","url":null,"abstract":"<p><strong>Objectives: </strong>To clarify the treatment reality of pancreatic cancer in Japan, focusing on treatment duration and time to death.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed Japanese hospital claims data for patients diagnosed with pancreatic cancer between April 2009 and October 2018 to investigate treatment patterns, duration of first-line chemotherapy, and time to death.</p><p><strong>Results: </strong>Of 81,185 eligible patients, 54.2% were male, the mean age was 71.7 years, and 23.3% (n = 18,884) received chemotherapy as primary treatment. The median treatment duration was 14.1 weeks for the 6.7% of patients who received oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX; recommended first-line regimen) and 16.9 weeks for the 30.2% of patients who received gemcitabine plus nab-paclitaxel (GEM + nab-PTX). Time to death for patients who received FOLFIRINOX or GEM + nab-PTX was similar (15.4 and 14.8 months, respectively). The duration of first-line chemotherapy regimens tended to increase annually for both regimens. The time to death for all first-line chemotherapy regimens also increased annually.</p><p><strong>Conclusions: </strong>This study revealed the treatment reality of pancreatic cancer in the real-world Japanese setting. Treatment duration and time to death tended to increase over time and did not differ numerically between FOLFIRINOX and GEM + nab-PTX.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e492-e500"},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Morphology of the Dorsal Pancreatic Artery and Its Oncological Significance in Pancreatic Cancer.","authors":"Takahiro Kyuno, Isamu Makino, Hirohisa Kitagawa, Hirofumi Terakawa, Ryosuke Gabata, Tomokazu Tokoro, Satoshi Takada, Mitsuyoshi Okazaki, Shinichi Nakanuma, Tetsuo Ohta, Shintaro Yagi","doi":"10.1097/MPA.0000000000002327","DOIUrl":"10.1097/MPA.0000000000002327","url":null,"abstract":"<p><strong>Objectives: </strong>Although the dorsal pancreatic artery (DPA) is an important artery that supplies the pancreas, its morphology has not been sufficiently studied. We investigated the morphology of the DPA and the progression of pancreatic cancer along this vessel.</p><p><strong>Materials and methods: </strong>Overall, 142 patients with pancreatic cancer who underwent surgical resection at Kanazawa University Hospital between 2004 and 2015 were enrolled. We examined the morphology of the DPA using preoperative computed tomography and cancer progression along the DPA using resected specimens. We investigated the anatomical structures surrounding the DPA through cadaveric examination.</p><p><strong>Results: </strong>The analysis of computed tomography images revealed the presence of the DPA in 141 patients. In typical cases, the DPA divides into a head and a body branch. Histopathological examination revealed cancer progression along the DPA in 32 patients. Cancer progression along the DPA was identified as a factor associated with a poor prognosis in pancreatic head or body cancer. Cadaveric examination showed the presence of abundant nerve and lymphatic tissues along the DPA.</p><p><strong>Conclusions: </strong>It is important to remove the soft tissue surrounding the DPA during surgery for pancreatic head or body cancer because it may serve as an important route for cancer progression.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e513-e520"},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Familial Intraductal Papillary Mucinous Neoplasm Associated With the Germline MSH6 Missense Variant and Progression of Pancreatic cancer.","authors":"Koji Tezuka, Mitsunori Yamakawa, Ryoko Murakami, Ichiro Hirai, Ryo Toya, Akihiko Suzuki, Hiroshi Kawamura, Yuki Miyano, Hidenori Sato, Fuyuhiko Motoi","doi":"10.1097/MPA.0000000000002313","DOIUrl":"10.1097/MPA.0000000000002313","url":null,"abstract":"<p><strong>Objectives: </strong>Intraductal papillary mucinous neoplasm (IPMN) in individuals with at least one first-degree relative with IPMN is defined as familial IPMN. However, few studies have reported on familial IPMN, its clinical characteristics, or the associated genetic factors.</p><p><strong>Materials and methods: </strong>We report the case of a 58-year-old woman with multifocal IPMN and a mural nodule in the pancreatic body. The patient underwent a distal pancreatectomy and developed pancreatic head cancer 1 year and 6 months postoperatively. The patient had a family history of multifocal IPMN in her father. Therefore, a genetic predisposition to IPMN and pancreatic cancer was suspected. The patient was analyzed for germline variants, and the resected IPMN was subjected to immunohistochemical and somatic variant analyses.</p><p><strong>Results: </strong>Next-generation sequencing revealed a heterozygous germline missense variant in exon 5 of MSH6 (c.3197A>G; Tyr1066Cys). The pathogenicity of this variant of uncertain significance was suspected based on multiple in silico analyses, and the same MSH6 variant was identified in the patient's father's colonic adenoma. The mural nodule in the pancreatic body was pathologically diagnosed as a high-grade IPMN with ossification and somatic KRAS and PIK3CA variants.</p><p><strong>Conclusions: </strong>This case revealed a possible genetic factor for familial IPMN development and presented interesting clinicopathological findings.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e476-e486"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PancreasPub Date : 2024-07-01Epub Date: 2024-06-03DOI: 10.1097/MPA.0000000000002379
Shweta Lavania
{"title":"Agi Hirshberg: Our Lady of Hope.","authors":"Shweta Lavania","doi":"10.1097/MPA.0000000000002379","DOIUrl":"10.1097/MPA.0000000000002379","url":null,"abstract":"","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":"53 6","pages":"e471-e475"},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001).","authors":"Hiroto Matsui, Tatsuya Ioka, Tsuyoshi Takahashi, Toru Kawaoka, Yoshinari Maeda, Noboru Yahara, Hidefumi Kubo, Taku Nishimura, Toshihiro Inokuchi, Eijiro Harada, Yoshitaro Shindo, Yukio Tokumitsu, Masao Nakajima, Taro Takami, Katsuyoshi Ito, Hidekazu Tanaka, Kimikazu Hamano, Hiroaki Nagano","doi":"10.1097/MPA.0000000000002323","DOIUrl":"10.1097/MPA.0000000000002323","url":null,"abstract":"<p><strong>Objectives: </strong>The present multicenter prospective observational study investigated the effectiveness and safety of neoadjuvant chemotherapy (NAC) for patients with borderline resectable pancreatic cancer (BRPC) and those with RPC contacting major vessels, with respect to a historical control of upfront surgery.</p><p><strong>Materials and methods: </strong>Patients with BRPC and RPC contacting major vessels were prospectively registered and administered NAC with durations and regimens determined by the corresponding treating physician. Our primary aim was to assess the R0 resection rate, and secondary aim was to evaluate safety, resection rate, time to treatment failure, overall survival, and response rate.</p><p><strong>Results: </strong>Fifty of 52 enrolled patients were analyzed; 2 with serious comorbidities died during treatment. Thirty-one patients underwent resection, with R0 resection being achieved in 26 (52% of total and 84% of all resected cases). Univariate and multivariate analyses indicated age (≥75 years) as the only independent predictor of nonresection. Median progression-free survival and median survival time were longer in the prospective cohort than in the historical cohort.</p><p><strong>Conclusions: </strong>Overall, NAC for BRPC in real-world setting might yield R0 resection rates similar to those reported in previous clinical studies. Development of safe regimens and management strategies that can maintain treatment intensity in geriatric patients is warranted.</p>","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e501-e512"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}